Pharmaceutical company’s boss, Emma Walmsley promised a ‘step-change in growth’ after better than expected results
GSK made £1.4bn from Covid-related medicines last year, beating earnings forecasts in its first financial results since rejecting Unilever’s £50bn buyout offer in December, as chief executive Emma Walmsley pledged “step-change in growth” in a landmark year.
The company is under the spotlight after promising to raise billions by spinning out its consumer arm, whose brands include Nicorette, Panadol and Aquafresh, in a London stock market listing this summer.
